Scientometrics Open Access
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. May 15, 2024; 15(5): 1021-1044
Published online May 15, 2024. doi: 10.4239/wjd.v15.i5.1021
Global status and trends of metabolomics in diabetes: A literature visualization knowledge graph study
Hong Li, Liu Li, Qiu-Qing Huang, Si-Yao Yang, Jun-Ju Zou, College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, Hunan Province, China
Fan Xiao, College of International Education, Hunan University of Chinese Medicine, Changsha 410208, Hunan Province, China
Qin Xiang, Department of Science and Technology, Hunan University of Chinese Medicine, Changsha 410208, Hunan Province, China
Xiu Liu, Rong Yu, Hunan Key Laboratory of TCM Prescription and Syndromes Translational Medicine, Hunan University of Chinese Medicine, Changsha 410208, Hunan Province, China
Rong Yu, College of Graduate, Hunan University of Chinese Medicine, Hunan Changsha, Hunan Province, China
ORCID number: Hong Li (0009-0000-4666-3617); Rong Yu (0000-0002-7950-218X).
Co-first authors: Hong Li and Xiu Liu.
Co-corresponding authors: Qin Xiang and Rong Yu.
Author contributions: Li H designed the study; Li H, Liu X, and Xiang Q participated in data processing and statistical analysis; Li H, Liu X, Huang QQ, and Yang SY drafted the manuscript; XF, Xiang Q and Zou JJ contributed to data analysis and interpretation; Xiang Q and Yu R supervised the review of the study; Li H and Liu X contributed equally to this work as co-first authors; Li H and Liu X collaborated closely on basic research related to this study, which inspired the writing of this study. Both authors have made crucial and indispensable contributions towards the completion of the project and thus qualified as the co-first authors of the manuscript; Xiang Q and Yu R have played important and indispensable roles in the data interpretation and manuscript supervision as the co-corresponding authors; Li H and Liu X as co-first authors and Xiang Q, and Yu R as co-corresponding authors, this is fitting for our manuscript as it accurately reflects our team's collaborative spirit, equal contributions, and diversity. all authors seriously revised and approved the final manuscript.
Supported by National Natural Science Foundation of China, No. U21A20411; and the Graduate Research and Innovation Project of Hunan Province, No. CX20220772.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rong Yu, PhD, Professor, Hunan Key Laboratory of TCM Prescription and Syndromes Translational Medicine, Hunan University of Chinese Medicine, No. 300 Bachelor Road, Bachelor Street, Yuelu District, Changsha 410208, Hunan Province, China. 1208466238@qq.com
Received: December 26, 2023
Peer-review started: December 27, 2023
First decision: January 17, 2024
Revised: January 28, 2024
Accepted: March 18, 2024
Article in press: March 18, 2024
Published online: May 15, 2024
Processing time: 136 Days and 8.9 Hours

Abstract
BACKGROUND

Diabetes is a metabolic disease characterized by hyperglycemia, which has increased the global medical burden and is also the main cause of death in most countries.

AIM

To understand the knowledge structure of global development status, research focus, and future trend of the relationship between diabetes and metabolomics in the past 20 years.

METHODS

The articles about the relationship between diabetes and metabolomics in the Web of Science Core Collection were retrieved from 2002 to October 23, 2023, and the relevant information was analyzed using CiteSpace6.2.2R (CiteSpace), VOSviewer6.1.18 (VOSviewer), and Bibliometrix software under R language.

RESULTS

A total of 3123 publications were included from 2002 to 2022. In the past two decades, the number of publications and citations in this field has continued to increase. The United States, China, Germany, the United Kingdom, and other relevant funds, institutions, and authors have significantly contributed to this field. Scientific Reports and PLoS One are the journals with the most publications and the most citations. Through keyword co-occurrence and cluster analysis, the closely related keywords are "insulin resistance", "risk", "obesity", "oxidative stress", "metabolomics", "metabolites" and "biomarkers". Keyword clustering included cardiovascular disease, gut microbiota, metabonomics, diabetic nephropathy, molecular docking, gestational diabetes mellitus, oxidative stress, and insulin resistance. Burst detection analysis of keyword depicted that "Gene", "microbiota", "validation", "kidney disease", "antioxidant activity", "untargeted metabolomics", "management", and "accumulation" are knowledge frontiers in recent years.

CONCLUSION

The relationship between metabolomics and diabetes is receiving extensive attention. Diabetic nephropathy, diabetic cardiovascular disease, and kidney disease are key diseases for future research in this field. Gut microbiota, molecular docking, and untargeted metabolomics are key research directions in the future. Antioxidant activity, gene, validation, mass spectrometry, management, and accumulation are at the forefront of knowledge frontiers in this field.

Key Words: Diabetes, Metabolomics, Bibliometric, CiteSpace, VOSviewer

Core Tip: Metabolomics is an important method to study diabetes, and we use bibliometrics to reveal the research status and future trends of the two. Through analysis and summary, diabetic nephropathy, diabetic cardiovascular disease, and kidney disease are key diseases for future research in this field. Gut microbiota, molecular docking, and untargeted metabolomics are key research directions in the future. Antioxidant activity, gene, validation, mass spectrometry, management, and accumulation are at the forefront of knowledge frontiers in this field.



INTRODUCTION

Previously, we believed that diabetes was a disease of developed countries and wealthy people[1]. In contrast, according to a survey by the International Diabetes Federation, it is estimated that 592 million people will have diabetes by 2035, of which 80% are low and middle-income people, which will bring heavy pressure and burden to global health care[2].

Metabolomics technology became increasingly common and received widespread attention in the scientific community[3]. Metabolomics can be used to diagnose disease, explore the mechanism of disease, new targets, and determine drug treatment and treatment results[4], especially in obesity, diabetes, cardiovascular disease, cancer, and neonatal metabolic defects[5-8].

At present, some scholars have used CiteSpace6.2.2R and VOSviewer6.1.18 software to analyze the literature on the correlation between gut flora and diabetes[9], but no one has paid attention to the correlation between metabolomics and diabetes, and we try to fill this knowledge gap. Bibliometrics has become an important tool for evaluating and analyzing the cooperation between universities, the output of scholars, the proportion of funds, and other information[10]. It is widely used in the medical community and provides a reasonable vision for the future through comprehensive measurement and evaluation[11]. This study is based on bibliometrics and visual atlas information to intuitively and systematically analyze the literature, aiming to reveal the publications, countries, institutions, funds, scholars, journals, citations, and keywords related to metabolomics and diabetes in the past 20 years and provide researchers with more detailed data support and future development directions.

MATERIALS AND METHODS
Data source

This study used the Web of Science Core Collection (WoSCC) as the data source, and two researchers searched it. Because of the different retrieval times and the slight increase or decrease in the amount of data, we chose one day to complete the retrieval task and determined the literature retrieval formula as follows: TS = (diabetes mellitus or diabetes or diabetic or diabetic mellitus or hyperglycemia) and TS = (metabolomic or metabolomics or metabonomic or metabonomics). The retrieval date was October 23, 2002-2023. The literature type was articles, and the language was limited to English (Figure 1).

Figure 1
Figure 1  Screening of research publications related to diabetes and metabolomic.
Statistics and analysis

After checking the included documents, we selected "plain text information", which contains the full records of the documents and the references quoted and named them as "download_*" format for export, respectively.

Microsoft Office Excel 2016 was used to make a tree chart and trend chart to describe the overall trend of the field, the number of published papers, and citations in each year. VOSviewer6.1.18 was deployed to describe the cooperation network relationships among countries, institutions, authors, and keywords. Different colors represent different years, nodes represent countries, authors, institutions and keywords, and the number of connections indicates the degree of cooperation. CiteSpace6.2.2R was utilized to predict future trends in the research field. It mainly displays keyword changes through keyword clustering, emergence, and timelines. Bibliometrix was employed to describe the national network map and the top ten authors, countries, institutions, etc.

RESULTS
Analysis of publications and citations

A total of 3123 articles on metabolomics and diabetes-related literature from 2002 to 2022 were included. Metabolomics and diabetes-related literature was first published in 2002 and sorted by year from 2002 to 2022. The annual number of publications and citations displayed an overall upward trend (Figure 2A). In total, 579 articles were published in 2022, with an annual number of 18887 citations. Up to the date of retrieval, due to the continuous updating of data in 2023, there are 459 articles as of October 23, 2023, and there will be more publications in this field in the future. As displayed in Figure 2B, the number of publications increased significantly from 2011 to 2012, 2015 to 2016, 2018 to 2019, and 2021 to 2022, while the annual growth fluctuation of citations generally increased reaching a maximum from 2020 to 2021.

Figure 2
Figure 2 Analysis of publications related to metabolomics and diabetes. A: Quantitative analysis of publications and citations; B: Analysis of annual changes in publications and citations.
Analysis of countries

The included publications were analyzed by country. The national map is revealed in Figure 3. A total of 95 countries have output publications (Figure 3A), displaying the cooperation among countries worldwide in this field. As presented in Figure 3B, a node represents a country, different colors of the circle represent different years, and the size of the node represents centrality. This figure illustrates 92 countries, of which China and the United States have the largest nodes, indicating that they are the most central. In Figure 3C, the VOSviewer displays a national density heatmap of no less than ten articles. The redder the color, the closer the cooperation connection. The countries in darker red are the United States, the United Kingdom, Germany, the Netherlands, Switzerland, and Finland. Regarding publication citations, Figure 3D displays the literature citations of the top 10 countries, followed by the United States, China, Germany, and the United Kingdom.

Figure 3
Figure 3 National analysis of the relationship between metabolomics and diabetes. A: Map of cooperation networks in all countries; B: Map of national central cooperation network; C: Density map of national cooperation network; D: Ranking map of publications in the top ten countries.
Analysis of institutions

The institution map is revealed in Figure 4. According to statistics, 3787 institutions participated in this research. As illustrated in Figure 4A, the most relevant institution is Harvard University (503 articles). According to the change chart of the number of publications issued by the top five institutions with the greatest relevance each year (Figure 4B), the Helmholtz Federation was at the top before 2018, and Harvard University occupied the first place after 2018. As revealed in Figure 4C, there were 180 institutions with more than 500 citations, which can be roughly divided into eight categories. The Chinese Academy of Sciences has the highest number of citations (5413 citations), followed by Duke University (5215 citations), and the University of Helsinki (4906 citations). Figure 4D depicts all institutions with a minimum threshold of 30. Institutions with strong centrality include the Chinese Academy of Sciences and Imperial College of Technology.

Figure 4
Figure 4 institution analysis of the relationship between metabolomics and diabetes. A: Ranking of top ten institutional publications; B: Time chart of top five institutional publications; C: Organization cooperation network map with more than 500 citations; D: Central cooperation relationship diagram of institutions.
Analysis of journals

As depicted in Figure 5A, the top ten journal publications are sorted, among which Scientific Reports has the largest number of publications, with a total of 106 publications, followed by Metabolomics (100 publications), Metabolites (92 publications), PLoS One (81 publications), and Journal of Project Research (78 publications). Figure 5B displays the journal density heatmap with more than 200 citations, which contains 113 journals and is divided into four different color modules. Among them, PLoS One has the largest number of citations (4553 citations), followed by Journal of Project Research (3232 citations), Diabetes (3154 citations), Scientific Reports (2905 citations), and Diabetologia (2783 citations). As revealed in Figure 5C, there are 22 core journals in this research field. We used CiteSpace to superimpose double graphs in the literature. As demonstrated in Figure 5D, the left side represents the collection of citing journals, and the right side represents the collection of cited journals. Citing journals are the knowledge frontiers, and the cited journals are the knowledge base. The diagram has four main paths, two of which are formed by crossing. The research literature on molecular, biology, immunology, medical, and clinical can support the results of molecular, biology, and genetics, and the research literature on medical, clinical, immunology, molecular, and biology can support the results of health, nursing, and medicine.

Figure 5
Figure 5 Journal analysis of the correlation between metabolomics and diabetes. A: Ranking of publications in the top ten journals; B: Density heat map of journal publications with more than 200 citations; C: Core journal collection; D: Journal double graph overlay.
Analysis of funds

According to statistics, analyzing the funds of all publications revealed 3746 fund projects in total. As presented in Figure 6A, the top ten funds are sorted. The different colored squares represent fund projects. The larger the square, the more frequently the funds appear. The top ten fund projects appear 2468 times, accounting for 83.638% of the total funds; the was the United States Department of Health Human Services (605 times). As illustrated in Figure 6B, the United States has three of the top ten funds, with a total frequency of 1341 times, while there is only one related fund in China, with a frequency of 594 times, accounting for 18.762%.

Figure 6
Figure 6 Fund analysis of the correlation between metabolomics and diabetes. A: Map of the proportion of top ten fund; B: Frequency and number of countries in the top ten fund project.
Analysis of authors and co-cited authors

Table 1 and Figure 7A reveal that 18239 scholars participated in this field. According to the ranking of the top ten authors, German scholars occupy the top two, and the number and centrality of publications by Jerzy Adamski scholars are the first (63 articles, 0.11) from Helmholtz Munich Center, Germany, while Guowang Xu (19 articles, 0.2) from Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China is the last. A total of 78607 scholars were also co-cited in this field. In Figure 7B, we included co-cited authors with more than 100 citations. As illustrated in Table 2, the first one was Thomas J Wang from Harvard Medical School, with 547 citations. There are two authors in the top ten columns regarding the number of publications and the number of co-cited authors, respectively, Karsten Suhre and Christopher Bang Newgard. As revealed in Figure 7, the numbers of co-cited authors and the cooperative relationship are closer.

Figure 7
Figure 7 Authors analysis of the relationship between metabolomics and diabetes. A: Author collaboration network map; B: Co-citated collaboration network map.
Table 1 The order of the top ten authors involved in the correlation between metabolomics and diabetes mellitus.
Rank
Number of publications
Centrality
Earliest time of posting
Author
Country
Institution
1630.112010Jerzy AdamskiGermanyHochschule Neubrandenburg
2310.012011Cornelia PrehnGermanyHelmholtz Center Munich - Environmental Health
3300.022011Karsten SuhreUnited StatesWeill Cornell Medical College
4300.012012Christopher Bang NewgardUnited StatesDuke University
5250.052012Robert E. GersztenUnited StatesBeth Israel Deaconess Medical Center
6240.052011Gabi KastenmüllerGermanyHelmholtz Zentrum München
7240.032006Mika Ala-KorpelaFinlandUniversity of Oulu
8200.022013Clary ClishUnited StatesHarvard University
9190.042009James R.
Bain
United StatesDuke University
10190.022009Guowang XuChinaDalian Institute of Chemical Physics Chinese Academy of Sciences
Table 2 The order of the top ten co-cited authors in the correlation between metabolomics and diabetes mellitus.
Rank
Number of publications
Centrality
Earliest time of publications
Author
Country
Institution
15470.022011Thomas J WangUnited StatesHarvard Medical School
24880.062010Christopher Bang NewgardUnited StatesDuke University
33710.042004Jeremy Kirk Nicholson United KingdomImperial College of Technology
433402008David Scott WishartCanadaUniversity of Alberta
531202012Anna FloegelGermanyHochschule Neubrandenburg
62400.032011Karsten SuhreUnited StatesWeill Cornell Medical College
723702014Peter WürtzFinlandNightingale Health
82110.012016Marta Guasch-FerréDenmarkUniversity of Copenhagen
92030.12003Oliver FiehnUnited StatesWest Coast Metabolomics Center
101970.022013Rui Wang-SattlerGermanyHelmholtz Center Munich
Analysis of highly cited references and co-cited publications

A total of 120514 references were cited in these publications, and the top ten references were counted (Table 3). "Metabolite profiles and the risk of developing diabetes", published by Wang et al[12] in Nature Medicine, has been cited the most (523 citations) in 2011. This article predicts the development of diabetes using metabolomics and correlates the age, body mass index, and fasting blood glucose of 2422 normal individuals and 201 patients with diabetes. Amino acid metabolism is potentially critical in the pathogenesis of diabetes, indicating that the amino acid spectrum can assess the risk of diabetes. The second is "A branched-chain amino acid (BCAA)-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance", published by Newgard et al[13] in Cell Metabolism in 2009, which has been cited 382 times. In this study, the metabolic characteristics of BCAA related metabolites were determined by metabonomic analysis of obese and thin people, and increased catabolism of BCAA was associated with insulin resistance (IR). It was confirmed that high-fat and BCAA fed mice induced IR with chronic phosphorylation of mTOR, JNK, IRS1 and accumulation of a variety of acylcarnitine in muscle, indicating that BCAA contributed to the development of obesity related IR. In 2013, Floegel et al[14] published " Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach ", which has been cited 275 times in Diabetes. This publication reveals the biomarkers of type 2 diabetes risk through targeted metabolomics. The data demonstrated that glucose metabolism, amino acids, and choline-containing phospholipids are highly correlated with type 2 diabetes in the early stages.

Table 3 Top 10 references in the correlation between metabolomics and diabetes mellitus.
Rank
Ref.
Title
Journal
Source (IF)
Citation
DOI
1Wang et al[12]Metabolite profiles and the risk of developing diabetesNature medicine82.952310.1038/NM.2307
2Newgard et al[13]A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistanceCell Metabolism2938210.1016/J.CMET.2009.02.002
3Floegel et al[14]Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approachDiabetes7.727510.2337/DB12-0495
4Wang-Sattler et al[60]Novel biomarkers for pre-diabetes identified by metabolomicsMolecular Systems Biology9.919410.1038/MSB.2012.43
5Guasch-Ferré et al[57]Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysisDiabetes Care16.218610.2337/DC15-2251
6Benjamini et al[61]Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple TestingJournal of the Royal Statistical Society: Series B (Methodological)5.815810.1111/j.2517-6161.1995.tb02031.x
7Nicholson et al[62]'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic dataXenobiotica1.815610.1080/004982599238047
8Suhre et al[63]Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological settingPlos one3.715610.1371/JOURNAL.PONE.0013953
9Menni et al[54]Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approachDiabetes7.715410.2337/DB13-0570
10Gall et al[64]Alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic populationPlos one3.714510.1371/JOURNAL.PONE.0010883

Simultaneously, we counted the top ten high-frequency publications (Table 4), with three publications cited more than 1000 times. The first is "Gut microbiota in human metabolic health and disease ", published by Fan et al[15] in Nature Reviews Microbiology in 2021, which has been cited 1339 times. This article reviews the role of the intestinal microbiota in human metabolic health and disease over the past two decades. Through the joint analysis of intestinal microbiota and multiomics, it aims to optimize the targeted intervention of microbiota in metabolic health to treat metabolic disorders, including diabetes, and understand how the intestinal microbiota affects the host's metabolism. The second is "Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity", published by Markle et al[16] in Science magazine in 2013, which has been cited 1262 times. The authors found that in a model of non-obese diabetic mice with type 1 diabetes, early microorganisms determined the level of sex hormones and changed autoimmunity, thus protecting non-obese diabetic male mice from the damage caused by type 1 diabetes. In addition, transferring the intestinal microbiota of adult male mice to immature female mice changes the microbiota of the receptor, resulting in changes in testosterone and metabolomics, affecting insulin and autoantibodies, and preventing the invasion of type 1 diabetes, which indicates the importance of androgen receptor activity. The third is "A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice", published by Plovier et al[17] in Nature Medicine in 2017, which has been cited 1128 times. They found that using Akkermansia muciniphila in mice can prevent the development of obesity and complications; however, the underlying mechanism is unclear. Therefore, extracting a specific protein isolated from the outer membrane of Akkermansia muciniphila is relatively stable at pasteurization temperatures and can interact with Toll-like receptor 2 to improve the intestinal barrier, thereby reducing the growth of fat and IR in mice. Finally, they demonstrated that Akkermansia muciniphila which grew in a synthetic medium or was pasteurized was safe for the human body and helped treat human obesity and related diseases.

Table 4 Top 10 co-cited literatures in the correlation between metabolomics and diabetes mellitus.
RankRef.TitleJournalSource (IF)Total citationsDOI
1Fan et al[15]Gut microbiota in human metabolic health and diseaseNature Reviews Microbiology88.1133910.1038/s41579-020-0433-9
2Markle et al[16]Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunityScience56.9126210.1126/science.1233521
3Plovier et al[17]A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic miceNature Medicine82.9112810.1038/nm.4236
4Rui Chen et al[65]Personal omics profiling reveals dynamic molecular and medical phenotypesCell64.584410.1016/j.cell.2012.02.009
5Wishart[4]Emerging applications of metabolomics in drug discovery and precision medicineNature Reviews Drug Discovery120.179210.1038/nrd.2016.32
6Suhre et al[66]Human metabolic individuality in biomedical and pharmaceutical researchNature64.874410.1038/nature10354
7Newgard[67]Interplay between lipids and branched-chain amino acids in development of insulin resistanceCell Metabolism2974010.1016/j.cmet.2012.01.024
8Floegel et al[15]Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approachDiabetes7.770810.2337/db12-0495
9Freemerman et al[68]Metabolic reprogramming of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotypeJournal Biological Chemistry4.854110.1074/jbc.M113.522037
10Guasch-Ferréet al[57]Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysisDiabetes Care16.253510.2337/dc15-2251
Analysis of keywords co-occurrence

Keywords are the core of the publication and can be used to analyze the research hotspots of the correlation between metabolomics and diabetes. Using the Bibliometrix software, the network relationships of the top 50 keywords were counted (Figure 8A), which were divided into blue and red. Nodes represent keywords, node size represents frequency, and connection thickness represents the relationship between the keywords. The blue part is closely related to IR, risk, metabolics, and biomarkers, whereas the red part is closely linked to obesity, metabolism, glucose, and disease. Figure 8B displays the frequencies and proportions of the top 50 keywords. A box represents a keyword, and the top ten keywords account for 41%. These included IR (621 times), risk (487 times), metabolomics (317 times), obesity (315 times), metabolism (273 times), biomarkers (257 times), plasma (241 times), disease (239 times), glucose (236 times), and oxidative stress (229 times). In Figure 8C, a node represents a keyword. The higher the centrality, the larger the circle. The color of the circle represents each year, and different colors represent different years. Showing the co-occurrence relationship of all keywords, the red color of the outer ring represents 2022, and the largest red density of the outer ring is gut microbiota. Using VOSviewer to count keywords, the keywords with a frequency of more than 100 times are displayed in the density map (Figure 8D). The redder the color, the higher the density value. A total of 40 keywords were counted, and the color of the metabolomics was the reddest.

Figure 8
Figure 8 Co-occurrence analysis of keywords related to metabolomics and diabetes. A: Network map of top 50 keywords; B: Block map of frequency and proportion of top 50 keywords; C: Centrality network map of keywords; D: Top 40 keywords density heat map.
Analysis of keywords clustering

All keywords were clustered, and eight types of tags were counted (Figure 9A). These include cardiovascular disease, gut microbiota, metabonomics, diabetic nephropathy, molecular docking, gestational diabetes mellitus, oxidative stress, and IR. Figure 9B depicts the broken-line peak diagram of each cluster label with the change in research intensity over time, where each color represents a cluster label. The cluster label cardiovascular disease peaked in 2014-2017, followed by a decline in popularity and a new peak in 2022. The cluster label gut microbiota has been hot continuously since 2010. The kurtosis of cluster label metabonomics was high from 2005 to 2008, after which the heat decreased. Although the clustering label diabetic nephropathy started earlier, its popularity continued to increase around 2010. Cluster label molecular docking was highly popular between 2020 and 2022. However, the relative popularity of cluster label gestational diabetes mellitus, cluster label oxidative stress, and cluster label IR were not high. Figure 9C the first 30 keywords into three clusters using multiple correspondence analysis. The first category of red markers involves important concepts in this field, which is highly consistent with the keywords in the fields related to diabetes and metabolomics. Obesity, mellitus, glucose, metabonomics, and disease are important factors. This group also emphasizes mass spectroscopy, IR, biomarkers, and serum, which have attracted considerable research interest. The category marked in blue is located in the second quadrant of the graph and is closely related to the mechanism of action in this field. The last cluster was green. Amino acids and branched chains are mainly involved in metabolomics. Figure 9D classifies the top 50 keywords into four categories: red, blue, green, and purple. Red and green emphasize the keywords related to metabolomics, purple emphasizes the keywords related to type 2 diabetes, and blue emphasizes the mechanism of action between the two.

Figure 9
Figure 9 Keywords cluster analysis of correlation between metabolomics and diabetes. A: Keywords clustering map label; B: Time variation map of keywords clustering; C: Multiple keywords correspondence analysis map; D: Clustering map of top 50 keywords.
Analysis of keywords bursts

CiteSpace can detect the emergence of keywords, reflecting new academic trends and research directions and revealing potential hotspots in the field. As revealed in Figure 10, it is divided into six parts: keywords, year, strength, begin, end, and time. Blue represents the timeline, and red represents the start year, end year, and duration of the burst. Through the analysis, we included 82 keywords with the highest burst intensity, and the highest burst intensity was "metabolomics (23.17 burst intensity)", followed by "systems biology (15.05 burst intensity)" and "NMR spectroscopy (13.66 burst intensity)". Among them, "metabolomics", "mass spectrometry", "urine", and "identification" have a longer duration. We were interested in burst words from 2018 onwards. It is expected that "gene", "glutathione", "validation", "microbiota", "kidney disease", "untargeted metabolomics", "management", "accumulation", and "antioxidant activity" will become the forefront of the discipline in this field. Currently, they are in an explosive stage.

Figure 10
Figure 10  Analysis of keywords related to metabolomics and diabetes by burst detection, including the top 82 burst words.
DISCUSSION

We searched for publications related to diabetes and metabolomics in WoSCC and retrieved 3123 publications. CiteSpace6.2.2R, VOSviewer6.1.18, and Bibliometrix were used to analyze and evaluate the temporal and spatial distribution, countries and institutions, core authors and literature, research hotspots, and knowledge frontiers. We learned that metabolomics and diabetes related publications were first published in 2002. Since then, the number of publications and citations has increased steadily, particularly since 2017, and the number of publications and citations has increased rapidly each year. It is expected that publications will continue to grow in the future, and the research in this field will continue to attract extensive attention from scholars in the future. The main conclusions are as follows.

Global knowledge structure

We know that the countries, funds, institutions, and authors are not individual entities but an organic whole that has a close relationship with each other. From the perspective of global cooperation, the countries of North America, Europe, and Asia are closely connected and have great influence, while those of South America and Africa are not connected enough, which may be linked to multiple factors such as population, economy, and healthcare.

North America is centered on the United States, which has the second-largest number of publications and the first-largest number of citations, indicating a great influence in this field, which may be closely related to the sponsorship of various funds in the United States, the contribution of major research institutions, core authors, and other factors. The number of fund sponsorships in the United States accounted for 42.356% of the global funds. It was not only strongly supported by the United States Department of Health and Human Services and the United States National Institutes of health but also independent of the Institute of Diabetes, which provided a good economic basis and special funding for scholars' research. In this field, the main research institutions in the United States include Harvard University, Harvard Medical School, Duke University, University of California, University of Michigan, and especially Harvard University, whose publications occupy the first. The comprehensive strengths of these universities provide a better research environment and platform for scholars. The strength of American scholars is relatively high, whether in terms of the number of publications by research scholars or the number of co-citations. The publications and citations of two scholars, Suhre Karsten and Newgard Christopher B, ranked in the top 10, while Thomas J Wang and Newgard Christopher B ranked first and second in terms of co-citations. Consequently, it can be explained that these factors have promoted the influence of the United States in the research on the correlation between diabetes and metabolomics, including the strong sponsorship of the United States Foundation and the high contribution of core scholars and research institutions.

Europe is also a hotspot in studying the correlation between diabetes and metabolomics. In terms of the number of publications and citations in all countries, the European countries accounted for the top 7/10. Germany and the United Kingdom have a significant influence. The Helmholtz Federation of Germany is highly influential. Adamski Jerzy, Prehn Cornelia, and Kasten Mueller Gabi occupy the first, second, and sixth places in the number of publications, respectively, all of which are from the Helmholtz Federation, which has promoted Germany's influence worldwide. In addition to the high proportion of funds in the United States, two of the top ten funds are funded by UK Research and Innovation and Medical Research Council. Jeremy K Nicholson, a scholar from the Imperial College of Technology, ranks third in terms of total citations and second in terms of centrality, indicating that his publications have received widespread attention worldwide.

Asia is centered on China, where the incidence of diabetes in China was observed to be increasingly higher[18,19]. Consequently, Chinese research institutions and scholars are committed to studying diabetes and its complications. The number of publications in China ranked first. Shanghai Jiao Tong University and the Chinese Academy of Sciences are major research institutions with potential. Among them, scholar Guowang Xu ranks among the top ten authors the number of publications. China's National Natural Science Foundation accounts for the second place. These favorable conditions fully indicate that China has great development potential in this field.

Similarly, when we want to deeply understand the research progress, direction, and results of the correlation between diabetes and metabolomics, we first consider the major journals, publications, co-cited references, and core authors in this field, which will bring new ideas and methods to our research. We can learn that most publications we selected first came from the top ten journals, such as Scientific Reports, Metabolomics, Metabolites, and PLoS One. Assuming that the scope is extended to a wider range, we can certainly search it from the core journals of diabetes and metabolomics correlation research (Figure 5C), which includes not only the top ten journals but also journals such as Diabetes Care and Journal of Pharmaceutical, which will provide more specific and extensive information to our research.

Global research priorities and trends

According to the co-occurrence of keywords, we can identify some hotspots and trends in the correlation between diabetes and metabolomics over the past two decades. These core keywords included IR, obesity, oxidative stress, metabolomics, risk, metabolism, and biomarkers.

The discovery of insulin was a milestone[20]. Human insulin is a peptide hormone comprising 51 amino acids and two chains. It is synthesized and released in the Langerhans pancreatic β cells and its main function is to maintain glucose homeostasis. Simultaneously, it is involved in glycogen synthesis, lipid metabolism, DNA synthesis, gene transcription, amino acid transport, protein synthesis, and degradation[21]. Insulin-mediated lack of glucose metabolic control in tissues induces IR[22]. An increasing number of studies have shown that IR is the main pathogenic factor in many metabolic diseases, including type 2 diabetes, obesity, and cardiovascular diseases[23,24]. Indeed, IR is a common feature in obesity and type 2 diabetes mellitus[25]. The prevalence of obesity has rapidly increased worldwide and has become a global public health concern[26,27]. Studies have demonstrated that obesity is not only related to an increased risk of cancer[28] but also increases the risk of type 2 diabetes, cardiovascular disease, musculoskeletal disease, and infection[29]. Obesity is the main risk factor for type 2 diabetes. Simultaneously, the high lipid content caused by obesity is the main factor that promotes IR[30]. IR, obesity, and diabetes are closely related, and they are related to inflammation, adipocyte dysfunction, oxidative stress, endoplasmic reticulum stress, aging, hypoxia, gene changes, and other mechanisms[31,32]. Oxidative stress is the imbalance between the oxidation and antioxidant systems of cells and tissues and results from excessive production of oxidative free radicals and related reactive oxygen species (ROS)[33]. Oxidative stress is associated with almost all major human diseases, including neurodegenerative diseases, cardiovascular diseases, and cancer[34]. Studies have disclosed that oxidative stress is the key mechanism of IR[35] and a key factor in the occurrence and development of diabetes and its related complications[36,37]. Under hyperglycemia, NF-κB, p38MAPK, PKC, and other signaling pathways are activated by ROS, which insulin signaling pathways, including phosphorylation of the INSR, IRS, activation of PI3K, and GLUT4, ultimately leading to IR[38]. Consequently, we can understand that the interaction between IR and oxidative stress is a potential mechanism of diabetes, and obesity and type 2 diabetes are causal to each other, providing a reasonable idea for the follow-up treatment of diabetes and complications. Combined with metabolomics, we can reveal its biomarkers and the mechanism of action behind the back, which is also a hot topic in studying the correlation between metabolomics and diabetes.

Metabolomics can empower diabetes research[39]. Metabolomics has been used to explore diabetes biomarkers to determine the occurrence, development, prognosis, and evaluation of diabetes. Some reports, combined with metabolomics, are from animals, and some reports are from humans. High-fat diet-induced IR in C57BL/6J mice depicted significant differences in lysine, glycine, citrate, leucine, octanoate, and acetate levels, and these metabolites were involved in energy metabolism[40]. Other studies[41] have found that taurine, creatinine, allantoin, and α-ketoglutarate increased in the fingerprint analysis of metabolites in the urine of Zucker obese and normal Wistar rats. In the urine metabolomics experiment of Zucker and GK rats[42], compared with normal rats, the creatine/creatinine, dimethylamine, and acetylacetic acid levels of Zucker and GK rats increased. Compared with Zucker rats, the levels of trimethylamine, acetate, and choline in GK rats decreased, while alanine, citrate, 2-ketoglutarate, succinate, lactic acid, hippurate, creatine/creatinine, and acetylacetic acid increased. There are metabolic similarities between the two stages of type 2 diabetes, including a decrease in the tricarboxylic acid cycle and an increase in ketone body production; the change in energy metabolism is greater in the hyperglycemia stage. In a study of db/db mice[43], carnitine, creatine, trimethylamine-N-oxide, and phenylalanine levels were significantly increased, and these metabolites may participate in the tricarboxylic acid cycle, fatty acid metabolism, and other pathways. In addition, it was reported[44] that based on the urine metabolomics of rhesus monkeys, a new compound, L-piperidic acid, was found, in which glycine, betaine, citric acid, kynurenine, piperidic acid, and glucose were significantly increased. Some scholars also used Akita mice to conduct metabonomic studies[45] on type 1 diabetes mellitus and found that BCAA, valine, leucine, proline, citrulline, and alanine were significantly increased.

Indeed, some studies[46] compare the urine metabolomics of mice, rats, and humans with type 2 diabetes. It is found that citrate, malic acid, fumarate, and aconitate are significantly increased in rats and mice. In contrast, malic acid, fumarate, and succinic acid levels are relatively reduced in humans. The concentrations of ketones and fatty acids are significantly increased in humans, mice, and rats, and the nucleotide metabolism is significantly changed. Similarly, the early and highly cited report in human metabolomics research[13] compared the data of amino acids, acylcarnitine, organic acids, and fatty acids in the plasma and urine of subjects with thin and fat people. Principal component analysis integration disclosed that the biggest differences between the two were leucine/isoleucine, valine, methionine, glutamic acid/glutamine, aromatic amino acids, phenylalanine amino acids, tyrosine, and C3 and C5 acylcarnitine. A linear correlation was observed between the metabolites of BCAA and Homeostasis Model Assessment of IR (P < 0.0001). Through the rat experiment, it was confirmed that the supplementation with BCAA, especially in the high-fat diet, could lead to the occurrence of IR. Previous studies have suggested that BCAA and aromatic amino acids are associated with obesity and IR[47]. There are also reports[48,49] that support this view. The BCAA levels decreased with weight loss. Subsequently, there is evidence[50] that BCAA and related metabolites can distinguish IR and insulin sensitivity between non-obese Chinese and non-obese Asian Indians. BCAA and their related metabolites are correlated with IR, even without obesity. Finally, the disorder of amino acid metabolism may be an early event in IR and type 2 diabetes. In a more valuable study[12], 422 normoglycemic individuals were followed up for 12 years, of which 201 had diabetes. Amino acids, amines, and other metabolites in the baseline samples were analyzed using liquid chromatography-tandem mass spectrometry. Significant differences were found in the five BCAA and aromatic cluster amino acids. Moreover, subsequent reports[51,52] further explained that amino acid metabolism may predict the risk of early diabetes. Certainly, some studies have found metabolites different from BCAA and aromatic amino acids. This study combined liquid chromatography tandem mass spectrometry, which can analyze 70 types of intermediate organic acids, purines, pyrimidines, and other compounds, to determine the risk markers and pathways of diabetes. It was found that 2-aminoadipic acid, which was decomposed by lysine metabolism, was most closely related to diabetes mellitus. The level of 2-aminoadipic acid is not highly correlated with BCAA or aromatic amino acids and has different physiological and pathological pathways. In addition to amino acid, organic acid, and nucleotide metabolism, there are reports of risk markers related to glucose and lipid metabolism. Studies[53] have predicted diabetes risk markers through the lipid metabolism spectrum. Comparing 189 type 2 diabetes and 189 matched disease-free individuals indicated that triacylglycerol with a low carbon value and double bond content was associated with increased diabetes risk. It was also reported that the metabolites in the serum of 9398 men were measured using nuclear magnetic resonance spectroscopy. It was found that glycerol, free fatty acids, and monounsaturated fat were biomarkers for the increased risk of type 2 diabetes. Impaired fasting glucose and glucose tolerance are markers of prediabetes. There are reports based on metabonomic studies of prediabetes[54,55], and α-hydroxybutyric acid is the most relevant marker of impaired glucose tolerance. Oleoylglyceride choline phosphate and oleic acid are selective markers of impaired glucose tolerance. BCKA 3-methyl-2-oxovalerate is the strongest predictor of impaired fasting glucose, which is second only to glucose and independent of glucose. Some studies[56] have found that biomarkers are negatively correlated with diabetes. Two groups of individuals in the Finnish Diabetes Prevention study believed that indole propionic acid is a derivative compound of the intestinal microbiota. It may be mediated by β cell function, plays a role in reducing inflammation, and partially combines with lipid-related metabolites, which have a protective effect on the development of type 2 diabetes. In short, different types of research on diabetes, studies across various regions and races, and investigations into different stages and mechanisms have been conducted in combination with metabolomics. Diabetes related metabolites were also identified, including amino acid metabolism, lipid metabolism, sugar metabolism, organic acid metabolism, nucleotide metabolism, and other pathways. In particular, BCAA and aromatic amino acids are significantly correlated with diabetes. This provides more data to support for promoting clinical diagnosis, treatment, and recovery.

Through keyword clustering, keyword clustering time change, and keywords emergence analysis, we can find the core and knowledge frontiers of future development. Cardiovascular disease, intestinal flora, diabetic nephropathy, and molecular docking in cluster analysis have demonstrated an increasing trend in recent years and are the core of this field in the future. The words "gene", "microbiota", "validation", "kidney disease", "antioxidant activity", "untargeted metabolomics", "management", and "accumulation" are burst words in recent years and are expected to be the knowledge frontiers of the future development of diabetes. Based on the algorithm (log likelihood ratio, p-level) in CiteSpace, closely related popular terms were obstained. The clustering labels for cardiovascular disease included metaeconomics, risk, and coronary artery disease. The clustering labels for gut microbiota included IR, type 2 diabetes, obesity, and high-fat diet. Clustering labels for diabetic nephropathy include chronic kidney disease, type 1 diabetes, kidney disease, and diabetic kidney disease. The clustering labels for molecular docking included antioxidant, identification, mass spectrometry, and alpha-glucosidase inhibition. In the future, research in this field may be conducted with the core keywords of cardiovascular disease, intestinal flora, diabetes nephropathy, and molecular docking cluster. Related popular terms under the cluster label can be cross-studied. Based on the hotspots of past research, combined with the explosive words of diabetes in recent years, we can try to conduct research from a new perspective.

Advantages and limitations

Compared with the previous systematic meta-analysis[57,58] and narrative evaluation[59] of diabetes and metabolomics-related research, this research is the first bibliometric research that has mapped research in this field into a knowledge map in the past two decades. We also used a different bibliometric software for visual analysis, which provided visual feedback and data support. It also combines past hotspots, future core, and knowledge frontiers in this field to provide more possibilities for new topics and directions. It is undeniable that WoSCC is currently the most commonly used and authoritative bibliometric database, but its data resources can only represent a certain field within a certain range. Moreover, due to the continuous updating of the database, the selection of database formats, manual screening and merging methods, and the built-in algorithms of bibliometric software, this inevitably brings about biases in our research. Finally, we believe our results can effectively represent diabetes and metabolomics research from the perspective of bibliometrics.

CONCLUSION

This study downloaded the publications on the relationship between diabetes and metabolomics from 2002 to 2022 through the WoSCC. Based on the bibliometric methods and perspectives, the number of publications in this field has continued to increase. The United States, China, Germany, the United Kingdom, and other relevant scholars, institutions, and funds have significantly contributed to this field. Through keyword co-occurrence analysis, we determined that IR, obesity, oxidative stress, metabolomics, risk, metabolites, and biomarkers were at the core of this field in the past. Diabetes involves the metabolism of amino acids, lipids, sugars, organic acids, nucleotides, and other pathways. BCAA and aromatic amino acids are strongly correlated with diabetes. Through keyword clustering, keyword clustering time change, and keyword emergence analysis, diabetes nephropathy, diabetes cardiovascular disease, and kidney disease are key diseases for future research in this field, with gut microbiota, molecular docking, and untargeted metabolomics being the focus of future research. Antioxidant activity, gene, validation, mass spectrometry, management, and accumulation are at forefront of knowledge reserves in this field.

ARTICLE HIGHLIGHTS
Research background

Diabetes is a metabolic disease characterized by hyperglycemia, which has increased the global medical burden and is also the main cause of death in most countries.

Research motivation

Metabolomics is an important method to study diabetes.

Research objectives

The purpose of this study is to understand the knowledge structure of global development status, research focus, and future trend of the relationship between diabetes and metabolomics in the past 20 years.

Research methods

We downloaded relevant data from Web of Science Core Collection, used CiteSpace6.2.2R, VOSviewer6.1.18, and Bibliometrix software under R language, and summarized the data.

Research results

A total of 3123 publications were included from 2002 to 2022. In the past two decades, the number of publications and citations in this field has continued to increase. The United States, China, Germany, the United Kingdom, and other relevant funds, institutions, and authors have significantly contributed to this field. Scientific Reports and PLoS One are the journals with the most publications and the most citations. Through keyword co-occurrence and cluster analysis, the closely related keywords are "insulin resistance", "risk", "obesity", "oxidative stress", "metabolomics", "metabolites", and "biomarkers". Keyword clustering included cardiovascular disease, gut microbiota, metabonomics, diabetic nephropathy, molecular docking, gestational diabetes mellitus, oxidative stress, and insulin resistance. Burst detection analysis of keyword depicted that "Gene", "microbiota", "validation", "kidney disease", "antioxidant activity", "untargeted metabolomics", "management", and "accumulation" are knowledge frontiers in recent years.

Research conclusions

Diabetic nephropathy, diabetic cardiovascular disease, and kidney disease are key diseases for future research in this field. Gut microbiota, molecular docking, and untargeted metabolomics are key research directions in the future. Antioxidant activity, gene, validation, mass spectrometry, management, and accumulation are at the forefront of knowledge reserves in this field.

Research perspectives

This study used bibliometric methods to explore the application of metabolomics in diabetes, and summarized the global trends and progress.

ACKNOWLEDGEMENTS

To provide the raw data for this work, we thank the Web of Science Core Collection.

Footnotes

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Endocrinology and metabolism

Country/Territory of origin: China

Peer-review report’s scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Al-Suhaimi EA, Saudi Arabia S-Editor: Lin C L-Editor: A P-Editor: Guo X

References
1.  Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 9344]  [Cited by in F6Publishing: 8778]  [Article Influence: 438.9]  [Reference Citation Analysis (1)]
2.  Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137-149.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2860]  [Cited by in F6Publishing: 2839]  [Article Influence: 283.9]  [Reference Citation Analysis (1)]
3.  Zeki ÖC, Eylem CC, Reçber T, Kır S, Nemutlu E. Integration of GC-MS and LC-MS for untargeted metabolomics profiling. J Pharm Biomed Anal. 2020;190:113509.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 60]  [Cited by in F6Publishing: 67]  [Article Influence: 16.8]  [Reference Citation Analysis (0)]
4.  Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov. 2016;15:473-484.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 753]  [Cited by in F6Publishing: 850]  [Article Influence: 106.3]  [Reference Citation Analysis (0)]
5.  Scolamiero E, Cozzolino C, Albano L, Ansalone A, Caterino M, Corbo G, di Girolamo MG, Di Stefano C, Durante A, Franzese G, Franzese I, Gallo G, Giliberti P, Ingenito L, Ippolito G, Malamisura B, Mazzeo P, Norma A, Ombrone D, Parenti G, Pellecchia S, Pecce R, Pierucci I, Romanelli R, Rossi A, Siano M, Stoduto T, Villani GR, Andria G, Salvatore F, Frisso G, Ruoppolo M. Targeted metabolomics in the expanded newborn screening for inborn errors of metabolism. Mol Biosyst. 2015;11:1525-1535.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 60]  [Cited by in F6Publishing: 63]  [Article Influence: 7.0]  [Reference Citation Analysis (0)]
6.  Newgard CB. Metabolomics and Metabolic Diseases: Where Do We Stand? Cell Metab. 2017;25:43-56.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 411]  [Cited by in F6Publishing: 468]  [Article Influence: 66.9]  [Reference Citation Analysis (0)]
7.  Iida M, Harada S, Takebayashi T. Application of Metabolomics to Epidemiological Studies of Atherosclerosis and Cardiovascular Disease. J Atheroscler Thromb. 2019;26:747-757.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 27]  [Cited by in F6Publishing: 46]  [Article Influence: 9.2]  [Reference Citation Analysis (0)]
8.  Huang Y, Du S, Liu J, Huang W, Liu W, Zhang M, Li N, Wang R, Wu J, Chen W, Jiang M, Zhou T, Cao J, Yang J, Huang L, Gu A, Niu J, Cao Y, Zong WX, Wang X, Qian K, Wang H. Diagnosis and prognosis of breast cancer by high-performance serum metabolic fingerprints. Proc Natl Acad Sci U S A. 2022;119:e2122245119.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5]  [Cited by in F6Publishing: 46]  [Article Influence: 23.0]  [Reference Citation Analysis (0)]
9.  Zhang L, Zhang H, Xie Q, Xiong S, Jin F, Zhou F, Zhou H, Guo J, Wen C, Huang B, Yang F, Dong Y, Xu K. A bibliometric study of global trends in diabetes and gut flora research from 2011 to 2021. Front Endocrinol (Lausanne). 2022;13:990133.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1]  [Cited by in F6Publishing: 7]  [Article Influence: 3.5]  [Reference Citation Analysis (0)]
10.  Moral-Munoz JA, Herrera-Viedma E, Santisteban-Espejo A, Cobo MJ. Software tools for conducting bibliometric analysis in science: An up-to-date review. Inf Prof. 2020;29.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 154]  [Cited by in F6Publishing: 169]  [Article Influence: 42.3]  [Reference Citation Analysis (0)]
11.  Mingers J, Leydesdorff L. A review of theory and practice in scientometrics. Eur J Oper Res. 2015;246:1-19.  [PubMed]  [DOI]  [Cited in This Article: ]
12.  Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17:448-453.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2121]  [Cited by in F6Publishing: 2286]  [Article Influence: 175.8]  [Reference Citation Analysis (0)]
13.  Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy WS Jr, Eisenson H, Musante G, Surwit RS, Millington DS, Butler MD, Svetkey LP. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009;9:311-326.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2212]  [Cited by in F6Publishing: 2282]  [Article Influence: 152.1]  [Reference Citation Analysis (0)]
14.  Floegel A, Stefan N, Yu Z, Mühlenbruch K, Drogan D, Joost HG, Fritsche A, Häring HU, Hrabě de Angelis M, Peters A, Roden M, Prehn C, Wang-Sattler R, Illig T, Schulze MB, Adamski J, Boeing H, Pischon T. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes. 2013;62:639-648.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 707]  [Cited by in F6Publishing: 733]  [Article Influence: 66.6]  [Reference Citation Analysis (0)]
15.  Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021;19:55-71.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 729]  [Cited by in F6Publishing: 1766]  [Article Influence: 441.5]  [Reference Citation Analysis (0)]
16.  Markle JG, Frank DN, Mortin-Toth S, Robertson CE, Feazel LM, Rolle-Kampczyk U, von Bergen M, McCoy KD, Macpherson AJ, Danska JS. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science. 2013;339:1084-1088.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1230]  [Cited by in F6Publishing: 1321]  [Article Influence: 120.1]  [Reference Citation Analysis (0)]
17.  Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, Chilloux J, Ottman N, Duparc T, Lichtenstein L, Myridakis A, Delzenne NM, Klievink J, Bhattacharjee A, van der Ark KC, Aalvink S, Martinez LO, Dumas ME, Maiter D, Loumaye A, Hermans MP, Thissen JP, Belzer C, de Vos WM, Cani PD. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2017;23:107-113.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 967]  [Cited by in F6Publishing: 1227]  [Article Influence: 153.4]  [Reference Citation Analysis (0)]
18.  Pan XR, Yang WY, Li GW, Liu J. Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group. Diabetes Care. 1997;20:1664-1669.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 371]  [Cited by in F6Publishing: 373]  [Article Influence: 13.8]  [Reference Citation Analysis (0)]
19.  Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-787.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3804]  [Cited by in F6Publishing: 3599]  [Article Influence: 156.5]  [Reference Citation Analysis (0)]
20.  Vecchio I, Tornali C, Bragazzi NL, Martini M. The Discovery of Insulin: An Important Milestone in the History of Medicine. Front Endocrinol (Lausanne). 2018;9:613.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 128]  [Cited by in F6Publishing: 88]  [Article Influence: 14.7]  [Reference Citation Analysis (0)]
21.  Cheatham B, Kahn CR. Insulin action and the insulin signaling network. Endocr Rev. 1995;16:117-142.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 46]  [Cited by in F6Publishing: 152]  [Article Influence: 5.2]  [Reference Citation Analysis (0)]
22.  James DE, Stöckli J, Birnbaum MJ. The aetiology and molecular landscape of insulin resistance. Nat Rev Mol Cell Biol. 2021;22:751-771.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 87]  [Cited by in F6Publishing: 211]  [Article Influence: 70.3]  [Reference Citation Analysis (0)]
23.  Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17:122.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 558]  [Cited by in F6Publishing: 899]  [Article Influence: 149.8]  [Reference Citation Analysis (0)]
24.  Lee SH, Park SY, Choi CS. Insulin Resistance: From Mechanisms to Therapeutic Strategies. Diabetes Metab J. 2022;46:15-37.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 49]  [Cited by in F6Publishing: 189]  [Article Influence: 94.5]  [Reference Citation Analysis (0)]
25.  Mastrototaro L, Roden M. Insulin resistance and insulin sensitizing agents. Metabolism. 2021;125:154892.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 41]  [Cited by in F6Publishing: 79]  [Article Influence: 26.3]  [Reference Citation Analysis (0)]
26.  GBD 2015 Obesity Collaborators; Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, Marczak L, Mokdad AH, Moradi-Lakeh M, Naghavi M, Salama JS, Vos T, Abate KH, Abbafati C, Ahmed MB, Al-Aly Z, Alkerwi A, Al-Raddadi R, Amare AT, Amberbir A, Amegah AK, Amini E, Amrock SM, Anjana RM, Ärnlöv J, Asayesh H, Banerjee A, Barac A, Baye E, Bennett DA, Beyene AS, Biadgilign S, Biryukov S, Bjertness E, Boneya DJ, Campos-Nonato I, Carrero JJ, Cecilio P, Cercy K, Ciobanu LG, Cornaby L, Damtew SA, Dandona L, Dandona R, Dharmaratne SD, Duncan BB, Eshrati B, Esteghamati A, Feigin VL, Fernandes JC, Fürst T, Gebrehiwot TT, Gold A, Gona PN, Goto A, Habtewold TD, Hadush KT, Hafezi-Nejad N, Hay SI, Horino M, Islami F, Kamal R, Kasaeian A, Katikireddi SV, Kengne AP, Kesavachandran CN, Khader YS, Khang YH, Khubchandani J, Kim D, Kim YJ, Kinfu Y, Kosen S, Ku T, Defo BK, Kumar GA, Larson HJ, Leinsalu M, Liang X, Lim SS, Liu P, Lopez AD, Lozano R, Majeed A, Malekzadeh R, Malta DC, Mazidi M, McAlinden C, McGarvey ST, Mengistu DT, Mensah GA, Mensink GBM, Mezgebe HB, Mirrakhimov EM, Mueller UO, Noubiap JJ, Obermeyer CM, Ogbo FA, Owolabi MO, Patton GC, Pourmalek F, Qorbani M, Rafay A, Rai RK, Ranabhat CL, Reinig N, Safiri S, Salomon JA, Sanabria JR, Santos IS, Sartorius B, Sawhney M, Schmidhuber J, Schutte AE, Schmidt MI, Sepanlou SG, Shamsizadeh M, Sheikhbahaei S, Shin MJ, Shiri R, Shiue I, Roba HS, Silva DAS, Silverberg JI, Singh JA, Stranges S, Swaminathan S, Tabarés-Seisdedos R, Tadese F, Tedla BA, Tegegne BS, Terkawi AS, Thakur JS, Tonelli M, Topor-Madry R, Tyrovolas S, Ukwaja KN, Uthman OA, Vaezghasemi M, Vasankari T, Vlassov VV, Vollset SE, Weiderpass E, Werdecker A, Wesana J, Westerman R, Yano Y, Yonemoto N, Yonga G, Zaidi Z, Zenebe ZM, Zipkin B, Murray CJL. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017;377:13-27.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3869]  [Cited by in F6Publishing: 4332]  [Article Influence: 618.9]  [Reference Citation Analysis (2)]
27.  Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15:288-298.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1741]  [Cited by in F6Publishing: 2284]  [Article Influence: 456.8]  [Reference Citation Analysis (0)]
28.  Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management. Cancers (Basel). 2023;15.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 86]  [Reference Citation Analysis (0)]
29.  Kivimäki M, Strandberg T, Pentti J, Nyberg ST, Frank P, Jokela M, Ervasti J, Suominen SB, Vahtera J, Sipilä PN, Lindbohm JV, Ferrie JE. Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study. Lancet Diabetes Endocrinol. 2022;10:253-263.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 146]  [Cited by in F6Publishing: 148]  [Article Influence: 74.0]  [Reference Citation Analysis (0)]
30.  Kojta I, Chacińska M, Błachnio-Zabielska A. Obesity, Bioactive Lipids, and Adipose Tissue Inflammation in Insulin Resistance. Nutrients. 2020;12.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 90]  [Cited by in F6Publishing: 178]  [Article Influence: 44.5]  [Reference Citation Analysis (0)]
31.  Wondmkun YT. Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications. Diabetes Metab Syndr Obes. 2020;13:3611-3616.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 115]  [Cited by in F6Publishing: 202]  [Article Influence: 50.5]  [Reference Citation Analysis (0)]
32.  Wu H, Ballantyne CM. Metabolic Inflammation and Insulin Resistance in Obesity. Circ Res. 2020;126:1549-1564.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 162]  [Cited by in F6Publishing: 411]  [Article Influence: 102.8]  [Reference Citation Analysis (0)]
33.  Newsholme P, Cruzat VF, Keane KN, Carlessi R, de Bittencourt PI Jr. Molecular mechanisms of ROS production and oxidative stress in diabetes. Biochem J. 2016;473:4527-4550.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 440]  [Cited by in F6Publishing: 517]  [Article Influence: 73.9]  [Reference Citation Analysis (0)]
34.  Ngo V, Duennwald ML. Nrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease. Antioxidants (Basel). 2022;11.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 77]  [Reference Citation Analysis (0)]
35.  Hurrle S, Hsu WH. The etiology of oxidative stress in insulin resistance. Biomed J. 2017;40:257-262.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 168]  [Cited by in F6Publishing: 255]  [Article Influence: 36.4]  [Reference Citation Analysis (0)]
36.  Rösen P, Nawroth PP, King G, Möller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev. 2001;17:189-212.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 638]  [Cited by in F6Publishing: 624]  [Article Influence: 27.1]  [Reference Citation Analysis (0)]
37.  Rains JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med. 2011;50:567-575.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 867]  [Cited by in F6Publishing: 892]  [Article Influence: 68.6]  [Reference Citation Analysis (1)]
38.  Ighodaro OM. Molecular pathways associated with oxidative stress in diabetes mellitus. Biomed Pharmacother. 2018;108:656-662.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 176]  [Cited by in F6Publishing: 233]  [Article Influence: 38.8]  [Reference Citation Analysis (0)]
39.  Beger RD, Dunn W, Schmidt MA, Gross SS, Kirwan JA, Cascante M, Brennan L, Wishart DS, Oresic M, Hankemeier T, Broadhurst DI, Lane AN, Suhre K, Kastenmüller G, Sumner SJ, Thiele I, Fiehn O, Kaddurah-Daouk R; for “Precision Medicine and Pharmacometabolomics Task Group”-Metabolomics Society Initiative. Metabolomics enables precision medicine: "A White Paper, Community Perspective". Metabolomics. 2016;12:149.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 403]  [Cited by in F6Publishing: 366]  [Article Influence: 45.8]  [Reference Citation Analysis (0)]
40.  Shearer J, Duggan G, Weljie A, Hittel DS, Wasserman DH, Vogel HJ. Metabolomic profiling of dietary-induced insulin resistance in the high fat-fed C57BL/6J mouse. Diabetes Obes Metab. 2008;10:950-958.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 109]  [Cited by in F6Publishing: 104]  [Article Influence: 6.5]  [Reference Citation Analysis (0)]
41.  Williams RE, Lenz EM, Evans JA, Wilson ID, Granger JH, Plumb RS, Stumpf CL. A combined (1)H NMR and HPLC-MS-based metabonomic study of urine from obese (fa/fa) Zucker and normal Wistar-derived rats. J Pharm Biomed Anal. 2005;38:465-471.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 97]  [Cited by in F6Publishing: 99]  [Article Influence: 5.2]  [Reference Citation Analysis (0)]
42.  Zhao LC, Zhang XD, Liao SX, Gao HC, Wang HY, Lin DH. A metabonomic comparison of urinary changes in Zucker and GK rats. J Biomed Biotechnol. 2010;2010:431894.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 25]  [Cited by in F6Publishing: 34]  [Article Influence: 2.4]  [Reference Citation Analysis (0)]
43.  Gipson GT, Tatsuoka KS, Ball RJ, Sokhansanj BA, Hansen MK, Ryan TE, Hodson MP, Sweatman BC, Connor SC. Multi-platform investigation of the metabolome in a leptin receptor defective murine model of type 2 diabetes. Mol Biosyst. 2008;4:1015-1023.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 20]  [Cited by in F6Publishing: 19]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]
44.  Patterson AD, Bonzo JA, Li F, Krausz KW, Eichler GS, Aslam S, Tigno X, Weinstein JN, Hansen BC, Idle JR, Gonzalez FJ. Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus. J Biol Chem. 2011;286:19511-19522.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 60]  [Cited by in F6Publishing: 57]  [Article Influence: 4.4]  [Reference Citation Analysis (0)]
45.  Mochida T, Tanaka T, Shiraki Y, Tajiri H, Matsumoto S, Shimbo K, Ando T, Nakamura K, Okamoto M, Endo F. Time-dependent changes in the plasma amino acid concentration in diabetes mellitus. Mol Genet Metab. 2011;103:406-409.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 26]  [Cited by in F6Publishing: 27]  [Article Influence: 2.1]  [Reference Citation Analysis (0)]
46.  Salek RM, Maguire ML, Bentley E, Rubtsov DV, Hough T, Cheeseman M, Nunez D, Sweatman BC, Haselden JN, Cox RD, Connor SC, Griffin JL. A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. Physiol Genomics. 2007;29:99-108.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 303]  [Cited by in F6Publishing: 314]  [Article Influence: 17.4]  [Reference Citation Analysis (0)]
47.  Felig P, Marliss E, Cahill GF Jr. Plasma amino acid levels and insulin secretion in obesity. N Engl J Med. 1969;281:811-816.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 581]  [Cited by in F6Publishing: 591]  [Article Influence: 10.7]  [Reference Citation Analysis (0)]
48.  Laferrère B, Reilly D, Arias S, Swerdlow N, Gorroochurn P, Bawa B, Bose M, Teixeira J, Stevens RD, Wenner BR, Bain JR, Muehlbauer MJ, Haqq A, Lien L, Shah SH, Svetkey LP, Newgard CB. Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci Transl Med. 2011;3:80re2.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 277]  [Cited by in F6Publishing: 288]  [Article Influence: 22.2]  [Reference Citation Analysis (0)]
49.  Shah SH, Crosslin DR, Haynes CS, Nelson S, Turer CB, Stevens RD, Muehlbauer MJ, Wenner BR, Bain JR, Laferrère B, Gorroochurn P, Teixeira J, Brantley PJ, Stevens VJ, Hollis JF, Appel LJ, Lien LF, Batch B, Newgard CB, Svetkey LP. Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss. Diabetologia. 2012;55:321-330.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 297]  [Cited by in F6Publishing: 267]  [Article Influence: 22.3]  [Reference Citation Analysis (0)]
50.  Tai ES, Tan ML, Stevens RD, Low YL, Muehlbauer MJ, Goh DL, Ilkayeva OR, Wenner BR, Bain JR, Lee JJ, Lim SC, Khoo CM, Shah SH, Newgard CB. Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. Diabetologia. 2010;53:757-767.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 353]  [Cited by in F6Publishing: 359]  [Article Influence: 25.6]  [Reference Citation Analysis (0)]
51.  Würtz P, Soininen P, Kangas AJ, Rönnemaa T, Lehtimäki T, Kähönen M, Viikari JS, Raitakari OT, Ala-Korpela M. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care. 2013;36:648-655.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 382]  [Cited by in F6Publishing: 397]  [Article Influence: 36.1]  [Reference Citation Analysis (0)]
52.  Chen T, Ni Y, Ma X, Bao Y, Liu J, Huang F, Hu C, Xie G, Zhao A, Jia W. Branched-chain and aromatic amino acid profiles and diabetes risk in Chinese populations. Sci Rep. 2016;6:20594.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 102]  [Cited by in F6Publishing: 123]  [Article Influence: 15.4]  [Reference Citation Analysis (0)]
53.  Rhee EP, Cheng S, Larson MG, Walford GA, Lewis GD, McCabe E, Yang E, Farrell L, Fox CS, O'Donnell CJ, Carr SA, Vasan RS, Florez JC, Clish CB, Wang TJ, Gerszten RE. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest. 2011;121:1402-1411.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 444]  [Cited by in F6Publishing: 482]  [Article Influence: 37.1]  [Reference Citation Analysis (0)]
54.  Menni C, Fauman E, Erte I, Perry JR, Kastenmüller G, Shin SY, Petersen AK, Hyde C, Psatha M, Ward KJ, Yuan W, Milburn M, Palmer CN, Frayling TM, Trimmer J, Bell JT, Gieger C, Mohney RP, Brosnan MJ, Suhre K, Soranzo N, Spector TD. Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes. 2013;62:4270-4276.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 303]  [Cited by in F6Publishing: 308]  [Article Influence: 28.0]  [Reference Citation Analysis (0)]
55.  Cobb J, Eckhart A, Motsinger-Reif A, Carr B, Groop L, Ferrannini E. α-Hydroxybutyric Acid Is a Selective Metabolite Biomarker of Impaired Glucose Tolerance. Diabetes Care. 2016;39:988-995.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 71]  [Cited by in F6Publishing: 78]  [Article Influence: 9.8]  [Reference Citation Analysis (0)]
56.  de Mello VD, Paananen J, Lindström J, Lankinen MA, Shi L, Kuusisto J, Pihlajamäki J, Auriola S, Lehtonen M, Rolandsson O, Bergdahl IA, Nordin E, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Landberg R, Eriksson JG, Tuomilehto J, Hanhineva K, Uusitupa M. Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study. Sci Rep. 2017;7:46337.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 154]  [Cited by in F6Publishing: 203]  [Article Influence: 29.0]  [Reference Citation Analysis (0)]
57.  Guasch-Ferré M, Hruby A, Toledo E, Clish CB, Martínez-González MA, Salas-Salvadó J, Hu FB. Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis. Diabetes Care. 2016;39:833-846.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 524]  [Cited by in F6Publishing: 587]  [Article Influence: 73.4]  [Reference Citation Analysis (0)]
58.  Long J, Yang Z, Wang L, Han Y, Peng C, Yan C, Yan D. Metabolite biomarkers of type 2 diabetes mellitus and pre-diabetes: a systematic review and meta-analysis. BMC Endocr Disord. 2020;20:174.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 30]  [Cited by in F6Publishing: 51]  [Article Influence: 12.8]  [Reference Citation Analysis (0)]
59.  Pallares-Méndez R, Aguilar-Salinas CA, Cruz-Bautista I, Del Bosque-Plata L. Metabolomics in diabetes, a review. Ann Med. 2016;48:89-102.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 74]  [Cited by in F6Publishing: 75]  [Article Influence: 9.4]  [Reference Citation Analysis (0)]
60.  Wang-Sattler R, Yu Z, Herder C, Messias AC, Floegel A, He Y, Heim K, Campillos M, Holzapfel C, Thorand B, Grallert H, Xu T, Bader E, Huth C, Mittelstrass K, Döring A, Meisinger C, Gieger C, Prehn C, Roemisch-Margl W, Carstensen M, Xie L, Yamanaka-Okumura H, Xing G, Ceglarek U, Thiery J, Giani G, Lickert H, Lin X, Li Y, Boeing H, Joost HG, de Angelis MH, Rathmann W, Suhre K, Prokisch H, Peters A, Meitinger T, Roden M, Wichmann HE, Pischon T, Adamski J, Illig T. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol. 2012;8:615.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 490]  [Cited by in F6Publishing: 524]  [Article Influence: 47.6]  [Reference Citation Analysis (0)]
61.  Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Series B Stat Methodol. 1995;.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 17030]  [Cited by in F6Publishing: 17347]  [Article Influence: 2891.2]  [Reference Citation Analysis (0)]
62.  Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29:1181-1189.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2918]  [Cited by in F6Publishing: 2626]  [Article Influence: 105.0]  [Reference Citation Analysis (0)]
63.  Suhre K, Meisinger C, Döring A, Altmaier E, Belcredi P, Gieger C, Chang D, Milburn MV, Gall WE, Weinberger KM, Mewes HW, Hrabé de Angelis M, Wichmann HE, Kronenberg F, Adamski J, Illig T. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One. 2010;5:e13953.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 477]  [Cited by in F6Publishing: 426]  [Article Influence: 30.4]  [Reference Citation Analysis (0)]
64.  Gall WE, Beebe K, Lawton KA, Adam KP, Mitchell MW, Nakhle PJ, Ryals JA, Milburn MV, Nannipieri M, Camastra S, Natali A, Ferrannini E; RISC Study Group. alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One. 2010;5:e10883.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 547]  [Cited by in F6Publishing: 497]  [Article Influence: 35.5]  [Reference Citation Analysis (0)]
65.  Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HY, Chen R, Miriami E, Karczewski KJ, Hariharan M, Dewey FE, Cheng Y, Clark MJ, Im H, Habegger L, Balasubramanian S, O'Huallachain M, Dudley JT, Hillenmeyer S, Haraksingh R, Sharon D, Euskirchen G, Lacroute P, Bettinger K, Boyle AP, Kasowski M, Grubert F, Seki S, Garcia M, Whirl-Carrillo M, Gallardo M, Blasco MA, Greenberg PL, Snyder P, Klein TE, Altman RB, Butte AJ, Ashley EA, Gerstein M, Nadeau KC, Tang H, Snyder M. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012;148:1293-1307.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 916]  [Cited by in F6Publishing: 856]  [Article Influence: 71.3]  [Reference Citation Analysis (0)]
66.  Suhre K, Shin SY, Petersen AK, Mohney RP, Meredith D, Wägele B, Altmaier E; CARDIoGRAM, Deloukas P, Erdmann J, Grundberg E, Hammond CJ, de Angelis MH, Kastenmüller G, Köttgen A, Kronenberg F, Mangino M, Meisinger C, Meitinger T, Mewes HW, Milburn MV, Prehn C, Raffler J, Ried JS, Römisch-Margl W, Samani NJ, Small KS, Wichmann HE, Zhai G, Illig T, Spector TD, Adamski J, Soranzo N, Gieger C. Human metabolic individuality in biomedical and pharmaceutical research. Nature. 2011;477:54-60.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 859]  [Cited by in F6Publishing: 801]  [Article Influence: 61.6]  [Reference Citation Analysis (0)]
67.  Newgard CB. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab. 2012;15:606-614.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 736]  [Cited by in F6Publishing: 770]  [Article Influence: 64.2]  [Reference Citation Analysis (0)]
68.  Freemerman AJ, Johnson AR, Sacks GN, Milner JJ, Kirk EL, Troester MA, Macintyre AN, Goraksha-Hicks P, Rathmell JC, Makowski L. Metabolic reprogramming of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. J Biol Chem. 2014;289: 7884-7896.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 480]  [Cited by in F6Publishing: 605]  [Article Influence: 60.5]  [Reference Citation Analysis (0)]